MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biotechnology company that develops therapies for inflammatory skin and joint disorders. The firm operates as a single-asset entity centered on the clinical evaluation of SLK, an investigational tri-specific Nanobody that inhibits interleukin-17A and interleukin-17F. Its research and development activities target inflammatory conditions within dermatology and rheumatology, primarily hidradenitis suppurativa, psoriatic arthritis, palmoplantar pustulosis, and axial spondyloarthritis. Because its therapeutic candidate remains in clinical development, the company has no commercial sales, and its intended end users are patients suffering from these inflammatory conditions.

The provided text does not identify the company's headquarters. In terms of operational scale and geography, the company conducts global clinical trial programs that encompass several international multi-center studies, as well as trial sites within the United States. Its clinical activities involve engagements with regulatory authorities, including the United States Food and Drug Administration and the European Medicines Agency. The company also utilizes external contract manufacturing organizations for drug substance and drug product manufacturing.

Summary of the business section of MoonLake Immunotherapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“We have grown to a team of approximately 130 employees as of December 31, 2025.”